A provider briefing on Humira Pen Starter Pack availability in 2026: biosimilar landscape, formulary shifts, prescribing implications, and tools.
If your patients are reporting difficulty filling prescriptions for the Humira Pen 40 Mg/0.4 Ml Starter Pack, they're not imagining things. While brand-name Humira (Adalimumab) is not in formal shortage, the U.S. market has undergone a fundamental transformation since the first biosimilars launched in January 2023.
This briefing covers what you need to know as a prescriber: the current availability picture, formulary implications, cost considerations, and tools to help your patients access treatment without interruption.
Understanding the current landscape requires context:
Major PBMs have restructured their formularies to favor biosimilars:
For patients initiating therapy, writing for a biosimilar from the start can eliminate prior authorization delays and improve time-to-treatment.
As of 2026, the following Adalimumab biosimilars carry FDA interchangeability designations: Amjevita, Cyltezo, Hyrimoz, Abrilada, Hulio, and Simlandi. In most states, pharmacists can substitute these for brand-name Humira without contacting the prescriber, unless "dispense as written" is indicated.
Clinical data supports that switching between the reference product and an interchangeable biosimilar does not result in clinically meaningful differences in efficacy, safety, or immunogenicity.
The Humira Pen Starter Pack (containing multiple pens for induction dosing) is a specialty configuration. As pharmacy inventory shifts toward biosimilars, this specific packaging has become harder to source. When initiating patients on Adalimumab therapy, consider whether a biosimilar with equivalent induction dosing is available in a comparable starter configuration.
Brand-name Humira is not on the FDA drug shortage list. However, practical availability varies:
Providers can use Medfinder for Providers to check real-time pharmacy availability and help patients identify pharmacies with their prescribed formulation in stock.
Cost remains a significant factor in treatment decisions:
| Product | List Price (2-pen carton) | vs. Humira |
|---|---|---|
| Humira (brand) | ~$6,900 | Reference |
| Hyrimoz (branded) | ~$6,576 | -5% |
| Hyrimoz (unbranded) | ~$1,315 | -81% |
| Hadlima | ~$1,038 | -85% |
| Amjevita | ~$3,100 | -55% |
For commercially insured patients, AbbVie's HUMIRA Complete Savings Card can reduce out-of-pocket costs to as little as $5/month. However, this is not available to government-insured patients.
Medicare Part D patients benefit from the Inflation Reduction Act's $2,100 annual out-of-pocket cap in 2026.
For uninsured patients, the myAbbVie Assist patient assistance program provides free medication to those who qualify. Biosimilar manufacturers also offer their own patient support programs.
The Adalimumab biosimilar market is maturing rapidly. Key trends to watch in 2026:
The Humira Pen 40 Mg/0.4 Ml Starter Pack availability challenge in 2026 reflects a market in transition, not a manufacturing shortage. As prescribers, you can help patients navigate this by staying current on formulary preferences, considering biosimilar alternatives when initiating therapy, and leveraging tools like Medfinder for Providers.
For a practical guide on helping patients locate their medication, see How to Help Your Patients Find Humira in Stock: A Provider's Guide. For patient-facing savings information to share, see How to Help Patients Save Money on Humira: A Provider's Guide.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
